Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
US treatment growth drives 23 percent increase in net revenue
Financial highlights Q2 2021
- Net sales amounted to 14 MSEK (11,4), an increase of 23 percent over the same period 2020.
- Operating result amounted to -9,4 MSEK (-9,0)
- Net result after financial items amounted to -9,7MSEK (-9,5)
- Earnings per share were -0,15 SEK (-0,17)
- Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 163 TSEK (109), an increase of 49 percent over the same period in 2020.
Financial highlights January - June 2021
- Net sales amounted to 27,2 MSEK (22,8), an increase of 19 percent over the same period 2020.
- Operating result amounted to -16,5 MSEK (-21,5)
- Net result after financial items amounted to -17,3 MSEK (-22,3)
- Earnings per share were -0,28 SEK (-0,40)
- Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 146 TSEK (106), an increase of 38 percent over the same period in 2020.
- The Annual General Meeting was held in Lund in May and resolved all proposed items in accordance with the announced proposals.
- In April Dignitana published the Annual Report for 2020.
Business highlights during the period
- Dignitana-backed insurance legislation in Texas did not come to a full vote prior to the close of the session in May.
Business highlights after the period
- In June Dignitana launched new initiatives to support reimbursement and market access in the US.
- Dignitana signed distributor B&Co Group to support Benelux Growth in July.
- The Board of Directors has appointed The Chairman of the Board Klas Arildsson to the role of a working Chairman supporting growth from an operational point of view. He will focus on Quality and Regulatory Affairs and operational efficiency.
Key Figures
+-----------------------+-------+-------+----------+----------+--------------+
|Dignitana Group |Q2 2021|Q2 2020|Q1-Q2 2021|Q1-Q2 2020|Full year 2020|
+-----------------------+-------+-------+----------+----------+--------------+
|Net revenues, TSEK |14 038 |11 423 |27 203 |22 816 |46 629 |
+-----------------------+-------+-------+----------+----------+--------------+
|Total revenues, TSEK |17 174 |11 876 |31 331 |24 353 |49 956 |
+-----------------------+-------+-------+----------+----------+--------------+
|Net profit after |-9 660 |-9 528 |-17 324 |-22 283 |-52 963 |
|financial items, TSEK | | | | | |
+-----------------------+-------+-------+----------+----------+--------------+
|Cash and bank balances,|36 333 |7 484 |36 333 |7 484 |78 770 |
|TSEK | | | | | |
+-----------------------+-------+-------+----------+----------+--------------+
|Earnings per share |-0,15 |-0,17 |-0,28 |-0,40 |-0,96 |
|before and after | | | | | |
|dilution, SEK | | | | | |
+-----------------------+-------+-------+----------+----------+--------------+
|Average Daily Treatment|163 |109 |146 |106 |120 |
|Revenue*, TSEK | | | | | |
+-----------------------+-------+-------+----------+----------+--------------+
* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-08-2021 08:00 CET.